THERMAL TREATMENT PROCESS FOR TOBACCO MATERIALS
    5.
    发明申请
    THERMAL TREATMENT PROCESS FOR TOBACCO MATERIALS 审中-公开
    烟草材料热处理工艺

    公开(公告)号:WO2012021683A3

    公开(公告)日:2012-05-31

    申请号:PCT/US2011047385

    申请日:2011-08-11

    Abstract: A method of preparing a tobacco material for use in a smoking article is provided, including (i) mixing a tobacco material, water, and an additive selected from the group consisting of lysine, glycine, histidine, alanine, methionine, glutamic acid, aspartic acid, proline, phenylalanine, valine, arginine, di- and trivalent cations, asparaginase, saccharides, phenolic compounds, reducing agents, compounds having a free thiol group, oxidizing agents, oxidation catalysts, plant extracts, and combinations thereof; (ii) heating the mixture; and (iii) incorporating the heat-treated mixture into a smoking article as a smokable material. A smoking article in the form of a cigarette is also provided that includes a tobacco material pre-treated to inhibit reaction of asparagine to form acrylamide in mainstream smoke. Upon smoking, the smoking article is characterized by an acrylamide content of mainstream smoke that is reduced relative to an untreated control smoking article.

    Abstract translation: 提供一种制备用于吸烟制品的烟草材料的方法,包括(i)将烟草材料,水和选自赖氨酸,甘氨酸,组氨酸,丙氨酸,甲硫氨酸,谷氨酸,天冬氨酸的添加剂混合 酸,脯氨酸,苯丙氨酸,缬氨酸,精氨酸,二价和三价阳离子,天冬酰胺酶,糖类,酚类化合物,还原剂,具有游离巯基的化合物,氧化剂,氧化催化剂,植物提取物及其组合; (ii)加热混合物; 和(iii)将热处理的混合物并入作为吸烟材料的吸烟制品中。 还提供了一种卷烟形式的吸烟制品,其包括预处理以抑制天冬酰胺在主流烟气中形成丙烯酰胺的反应的烟草材料。 吸烟时,吸烟制品的特征在于主流烟雾的丙烯酰胺含量相对于未处理的对照吸烟制品而减少。

    REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF SPINAL CORD INJURY AND ALS

    公开(公告)号:WO2021076983A1

    公开(公告)日:2021-04-22

    申请号:PCT/US2020/056108

    申请日:2020-10-16

    Inventor: CHEN, Gong

    Abstract: This document provides methods and materials involved in treating mammals having a spinal cord injury (SCI). For example, methods and materials for administering a composition containing exogenous nucleic acid encoding a NeuroD1polypeptide (or a biologically active fragment thereof) alone or in combination with a Dlx2 polypeptide (or a biologically active fragment thereof) to a mammal having SCI are provided. This document also provides methods and materials involved in treating mammals having amyotrophic lateral sclerosis (ALS). For example, methods and materials for administering a composition containing exogenous nucleic acid encoding a NeuroD1 polypeptide (or a biologically active fragment thereof) alone or in combination with an Isl1 polypeptide (or a biologically active fragment thereof) to a mammal having ALS are provided.

Patent Agency Ranking